keyword
MENU ▼
Read by QxMD icon Read
search

Ckd mineral bone disease

keyword
https://www.readbyqxmd.com/read/29905968/skeletal-consequences-of-nephropathic-cystinosis
#1
Pablo Florenzano, Carlos Ferreira, Galina Nesterova, Mary Scott Ramnitz, Sri Harsha Tella, Luis Fernandez de Castro, Sydney M Brown, Adom Whitaker, Renata C Pereira, Dorothy Bulas, Rachel I Gafni, Isidro B Salusky, William A Gahl, Michael T Collins
Nephropathic cystinosis is a rare lysosomal storage disorder. Patients present in the first year of life with renal Fanconi syndrome that evolves to progressive chronic kidney disease (CKD). Despite the multiple risk factors for bone disease, the frequency and severity of skeletal disorders in nephropathic cystinosis have not been described. We performed systematic bone and mineral evaluations of subjects with cystinosis seen at the NIH (N = 30), including history and physical examination, serum and urine biochemistries, DXA, vertebral fracture assessment, skeletal radiographs, and renal ultrasound...
June 15, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29882003/prevalence-and-risk-factors-for-hypercalcemia-among-non-dialysis-patients-with-chronic-kidney-disease-mineral-and-bone-disorder
#2
Jun Jie Benjamin Seng, Ying Lin Cheryl Tan, Rou Wei Lim, Hui Ting Sarah Ng, Puay Hoon Lee, Jiunn Wong
PURPOSE: To examine the prevalence and risk factors for hypercalcemia among non-dialysis chronic kidney disease (CKD) patients with mineral and bone disorder (MBD). METHODS: A retrospective cohort study was conducted in Singapore General Hospital, involving all CKD stage 4 and 5 pre-dialysis patients who were on treatment for MBD in June 2016. Each patient was followed up for 1 year and screened for hypercalcemia episodes. Mild, moderate and severe hypercalcemia were defined as corrected calcium of 2...
June 7, 2018: International Urology and Nephrology
https://www.readbyqxmd.com/read/29872964/the-interplay-between-bone-and-vessels-in-pediatric-ckd-lessons-from-a-single-center-study
#3
Evgenia Preka, Bruno Ranchin, Anke Doyon, Melody Vierge, Tiphanie Ginhoux, Behrouz Kassai, Justine Bacchetta
OBJECTIVE: Mineral and bone disorders associated to chronic kidney disease (CKD-MBD) are a daily challenge for pediatric nephrologists, with a significant risk of long-term bone and vascular comorbidities. METHODS: This single-center study is a prospective transversal evaluation of pediatric CKD patients of our center, part of the European 4C study. In addition to clinical and biochemical data, vascular and bone evaluation was performed: 24-h blood pressure assessment, carotid intima-media thickness (cIMT), pulse wave velocity (PWV), and high-resolution peripheral quantitative computed tomography (HR-pQCT) at the ultra-distal tibia...
June 5, 2018: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/29864403/effect-of-uremic-toxin-indoxyl-sulfate-on-the-skeletal-system
#4
REVIEW
Wen-Chih Liu, Chia-Chao Wu, Paik-Seong Lim, Shiaw-Wen Chien, Yi-Chou Hou, Cai-Mei Zheng, Jia-Fwu Shyu, Yuh-Feng Lin, Kuo-Cheng Lu
Chronic kidney disease-mineral bone disorders (CKD-MBD) exhibit abnormalities in the circulating mineral levels, vitamin D metabolism, and parathyroid function that contribute to the formation of a bone lesion. The uremic toxin, indoxyl sulfate (IS), accumulates in the blood in cases of renal failure and leads to bone loss. The bone and renal responses to the action of the parathyroid hormone (PTH) are progressively decreased in CKD in spite of increasing PTH levels, a condition commonly called PTH resistance...
June 1, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29860153/magnetic-resonance-imaging-based-assessment-of-bone-microstructure-as-a-non-invasive-alternative-to-histomorphometry-in-patients-with-chronic-kidney-disease
#5
Ashish K Sharma, Nigel D Toussaint, Grahame J Elder, Rosemary Masterson, Stephen G Holt, Patricia L Robertson, Peter R Ebeling, Paul Baldock, Rhiannon C Miller, Chamith S Rajapakse
BACKGROUND: Chronic kidney disease (CKD) adversely affects bone microarchitecture and increases fracture risk. Historically, bone biopsy has been the 'gold standard' for evaluating renal bone disease but is invasive and infrequently performed. High-resolution magnetic resonance imaging (MRI) quantifies bone microarchitecture noninvasively. In patients with CKD, it has not been compared with results derived from bone biopsy or with imaging using dual energy X-ray absorptiometry (DXA). METHODS: Fourteen patients with end-stage kidney disease (ESKD) underwent MRI at the distal tibia, bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA; hip and spine) and transiliac bone biopsies with histomorphometry and microcomputed tomography (micro-CT)...
May 31, 2018: Bone
https://www.readbyqxmd.com/read/29846719/effects-of-sucroferric-oxyhydroxide-and-sevelamer-carbonate-on-chronic-kidney-disease-mineral-bone-disorder-parameters-in-dialysis-patients
#6
Markus Ketteler, Stuart M Sprague, Adrian C Covic, Anjay Rastogi, Bruce Spinowitz, Viatcheslav Rakov, Sebastian Walpen, Jürgen Floege
Background: Treatment of hyperphosphataemia is the primary goal of chronic kidney disease-mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate ('sevelamer') on CKD-MBD indices among dialysis patients with hyperphosphataemia. Methods: After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1...
May 29, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29846712/sclerostin-in-chronic-kidney-disease-mineral-bone-disorder-think-first-before-you-block-it
#7
Vincent M Brandenburg, Anja Verhulst, Anne Babler, Patrick C D'Haese, Pieter Evenepoel, Nadine Kaesler
Canonical Wnt signalling activity is a major player in physiological and adaptive bone metabolism. Wnt signalling is regulated by soluble inhibitors, with sclerostin being the most widely studied. Sclerostin's main origin is the osteocyte and its major function is blockade of osteoblast differentiation and function. Therefore, sclerostin is a potent inhibitor of bone formation and mineralization. Consequently, blocking sclerostin via human monoclonal antibodies (such as romosozumab) represents a promising perspective for the treatment of (postmenopausal) osteoporosis...
May 24, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29808090/role-of-the-wnt-%C3%AE-catenin-pathway-in-renal-osteodystrophy
#8
REVIEW
Sarah-Kim Bisson, Roth-Visal Ung, Fabrice Mac-Way
Vascular calcification and bone fragility are common and interrelated health problems that affect chronic kidney disease (CKD) patients. Bone fragility, which leads to higher risk of fracture and mortality, arises from the abnormal bone remodeling and mineralization that are seen in chronic kidney disease. Recently, sclerostin and Dickkopf-related protein 1 were suggested to play a significant role in CKD-related bone disease as they are known inhibitors of the Wnt pathway, thus preventing bone formation. This review focuses on new knowledge about the Wnt pathway in bone, how its function is affected by chronic kidney disease and how this affects bone structure...
2018: International Journal of Endocrinology
https://www.readbyqxmd.com/read/29796575/evaluation-of-prevalence-biochemical-profile-and-drugs-associated-with-chronic-kidney-disease-mineral-and-bone-disorder-in-11-dialysis-centers
#9
Rodrigo Reis Abrita, Beatriz Dos Santos Pereira, Neimar da Silva Fernandes, Renata Abrita, Rosalia Maria Nunes Henriques Huaira, Marcus Gomes Bastos, Natália Maria da Silva Fernandes
INTRODUCTION: The diagnosis and treatment of mineral and bone disorder of chronic kidney disease (CKD-MBD) is a challenge for nephrologists and health managers. The aim of this study was to evaluate the prevalence, biochemical profile, and drugs associated with CKD-MBD. METHODS: Cross-sectional study between July and November 2013, with 1134 patients on dialysis. Sociodemographic, clinical, and laboratory data were compared between groups based on levels of intact parathyroid hormone (iPTH) (< 150, 150-300, 301-600, 601-1000, and > 1001 pg/mL)...
January 2018: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29795756/discovery-of-orally-bioavailable-selective-inhibitors-of-the-sodium-phosphate-cotransporter-napi2a-slc34a1
#10
Kevin J Filipski, Matthew F Sammons, Samit K Bhattacharya, Jane Panteleev, Janice A Brown, Paula M Loria, Markus Boehm, Aaron C Smith, Andre Shavnya, Edward L Conn, Kun Song, Yan Weng, Carie Facemire, Harald Jüppner, Valerie Clerin
Sodium-phosphate cotransporter 2a, or NaPi2a (SLC34A1), is a solute-carrier (SLC) transporter located in the kidney proximal tubule that reabsorbs glomerular-filtered phosphate. Inhibition of NaPi2a may enhance urinary phosphate excretion and correct maladaptive mineral and hormonal derangements associated with increased cardiovascular risk in chronic kidney disease-mineral and bone disorder (CKD-MBD). To date, only nonselective NaPi inhibitors have been described. Herein, we detail the discovery of the first series of selective NaPi2a inhibitors, resulting from optimization of a high-throughput screening hit...
May 10, 2018: ACS Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29792935/lp533401-restores-bone-health-in-5-6-nephrectomized-rats-by-a-decrease-of-gut-derived-serotonin-and-regulation-of-serum-phosphate-through-the-inhibition-of-phosphate-co-transporters-expression-in-the-kidneys
#11
Dariusz Pawlak, Beata Znorko, Bartlomiej Kalaska, Tomasz Domaniewski, Radosław Zawadzki, Paweł Lipowicz, Michał Doroszko, Urszula Łebkowska, Piotr Grabowski, Krystyna Pawlak
LP533401 is an orally bioavailable small molecule that inhibits tryptophan hydroxylase-1, an enzyme responsible for the synthesis of gut-derived serotonin (GDS). Recently, we showed that increased GDS in rats with chronic kidney disease (CKD) affected bone strength and metabolism. We tested the hypothesis that treatment with LP533401 could reverse CKD-induced bone loss in uremia. Sixteen weeks after 5/6 nephrectomy, rats were randomized into untreated (CKD), treated with vehicle (VEH) and LP533401 at a dose of 30 or 100 mg/kg daily for 8 weeks...
May 21, 2018: Bone
https://www.readbyqxmd.com/read/29791896/deterioration-of-cortical-bone-microarchitecture-critical-component-of-renal-osteodystrophy-evaluation
#12
Ashish K Sharma, Nigel D Toussaint, Rosemary Masterson, Stephen G Holt, Chamith S Rajapakse, Peter R Ebeling, Sindhu T Mohanty, Paul Baldock, Grahame J Elder
BACKGROUND: Cortical bone is a significant determinant of bone strength and its deterioration contributes to bone fragility. Thin cortices and increased cortical porosity have been noted in patients with chronic kidney disease (CKD), but the "Turnover Mineralization Volume" classification of renal osteodystrophy does not emphasize cortical bone as a key parameter. We aimed to assess trabecular and cortical bone microarchitecture by histomorphometry and micro-CT in patients with CKD G5 and 5D (dialysis)...
May 23, 2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29786181/-new-scenarios-in-secondary-hyperparathyroidism-etelcalcetide-position-paper-of-nephrologists-form-lombardy
#13
Antonio Bellasi, Mario Cozzolino, Fabio Malberti, Giovanni Cancarini, Ciro Esposito, Augusto Genderini, Carlo Maria Guastoni, Patrizia Ondei, Giuseppe Pontoriero, Ugo Teatini, Giuseppe Vezzoli, Piergiorgio Messa, Francesco Locatelli
Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities...
May 2018: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/29786179/-update-2017-of-the-kdigo-guidelines-on-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd-what-are-the-real-changes
#14
Marzia Pasquali, Antonio Bellasi, Giuseppe Cianciolo, Carlo Massimetti, Maria Cristina Mereu, Luigi Morrone, Vincenzo Panuccio
Guidelines for the assessment, diagnosis and therapy of the alterations that characterize the CKD-MBD are an important support in the clinical practice of the nephrologist. Compared to the KDIGO guidelines published in 2009, the 2017 update made changes on some topics on which there was previously no strong evidence both in terms of diagnosis and therapy. The recommendations include the diagnosis of bone anomalies in CKD-MBD and the treatment of mineral metabolism abnormalities with particular regard to hyperphosphataemia, calcium levels, secondary hyperparathyroidism and anti-resorptive therapies...
May 2018: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/29782253/-mineral-and-bone-disorders-in-chronic-heart-failure
#15
E V Reznik, I G Nikitin
In many patients, chronic heart failure (CHF) is associated with chronic kidney disease (CKD). Virtually all patients with terminal CKD and many patients with early CKD display various disorders of mineral and bone metabolism (MBM) related with all-cause mortality and high risk of cardiovascular complications. This review addressed disorders of mineral and bone metabolism in patients with CHF, including hypocalcemia, hyperphosphatemia, vitamin D insufficiency/deficiency, secondary hyperparathyroidism, changed levels of FGF23 and Klotho, osteoporosis, osteopenia, their clinical and prognostic significance, and possibilities of their correction...
2018: Kardiologiia
https://www.readbyqxmd.com/read/29781225/critical-governance-issue-of-parathyroid-hormone-assays-and-its-selection-in-the-management-of-chronic-kidney-disease-mineral-and-bone-disorders
#16
REVIEW
Takatoshi Kakuta, Mari Ishida, Masafumi Fukagawa
Measurement of circulating parathyroid hormone (PTH) levels is essential for optimal management of mineral and bone disorders (MBD) in chronic kidney disease (CKD) patients. There are two major types of PTH assays currently in use: intact parathyroid hormone (i-PTH) and whole PTH (w-PTH) assays. The i-PTH assay is the current standard, and considerable information regarding the management of CKD-MBD has been obtained with this method. However, several limitations have been found with the i-PTH assay. One limitation is that i-PTH assay also measures fragments other than full-length PTH (1-84)...
May 20, 2018: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/29780418/biological-and-clinical-effects-of-calciprotein-particles-on-chronic-kidney-disease-mineral-and-bone-disorder
#17
REVIEW
Kenichi Akiyama, Takaaki Kimura, Kazuhiro Shiizaki
Calciprotein particles (CPPs) are a new biological marker of chronic kidney disease-mineral and bone disorder (CKD-MBD). CPPs consist of phosphate, calcium, and some proteins, with phosphate being the major contributor to the level and biological activity of CPPs. Recent studies have shown the physiological and pathological significance of CPPs, including contributions to bone and mineral metabolism, and to tissue and organ impairments such as cardiovascular damage and inflammatory responses. These actions are well known as important aspects of CKD-MBD...
2018: International Journal of Endocrinology
https://www.readbyqxmd.com/read/29779028/dietary-changes-involving-bifidobacterium-longum-and-other-nutrients-delays-chronic-kidney-disease-progression
#18
Yuko Iwashita, Masaki Ohya, Mitsuru Yashiro, Tomohiro Sonou, Kazuki Kawakami, Yuri Nakashima, Takuro Yano, Yu Iwashita, Toru Mima, Shigeo Negi, Kaoru Kubo, Koichi Tomoda, Toshitaka Odamaki, Takashi Shigematsu
BACKGROUND: Recent studies suggest that prebiotic and/or probiotic treatments ameliorate kidney function in humans and animals by improving the gut environment. However, the gut microbiota and kidney disease interactions remain to be determined. This study investigated whether synbiotics modulate the gut microbiota and ameliorate kidney function using a rat model of chronic kidney disease (CKD). As uremic toxins are associated with CKD-related mineral and bone disorder, the secondary aim was to evaluate the relationship between synbiotics and secondary hyperparathyroidism (SHPT)...
2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29775762/aortic-vascular-calcification-is-inversely-associated-with-the-trabecular-bone-score-in-patients-receiving-dialysis
#19
Jasna Aleksova, Samantha Kurniawan, Mirna Vucak-Dzumhur, Peter Kerr, Peter R Ebeling, Frances Milat, Grahame J Elder
INTRODUCTION: Progressive chronic kidney disease (CKD) confers a marked increase in risk for vascular calcification, cardiovascular disease, fracture and mortality, with likely contributing factors including dysregulated bone metabolism and mineral homeostasis. In general population studies, increased vascular calcification is directly related to mortality and inversely related to bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA). In patients with CKD, abnormalities in turnover, mineralization and bone volume, reduce the ability of DXA to predict fracture...
May 15, 2018: Bone
https://www.readbyqxmd.com/read/29772660/role-of-uremic-toxins-for-kidney-cardiovascular-and-bone-dysfunction
#20
REVIEW
Hideki Fujii, Shunsuke Goto, Masafumi Fukagawa
With decreasing kidney function, cardiovascular disease (CVD) and mineral bone disorders frequently emerge in patients with chronic kidney disease (CKD). For these patients, in addition to the traditional risk factors, non-traditional CKD-specific risk factors are also associated with such diseases and conditions. One of these non-traditional risk factors is the accumulation of uremic toxins (UTs). In addition, the accumulation of UTs further deteriorates kidney function. Recently, a huge number of UTs have been identified...
May 16, 2018: Toxins
keyword
keyword
118711
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"